Clinical Trials Logo

MSI-H Colorectal Cancer clinical trials

View clinical trials related to MSI-H Colorectal Cancer.

Filter by:

NCT ID: NCT04244552 Terminated - Breast Cancer Clinical Trials

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Start date: February 11, 2020
Phase: Phase 1
Study type: Interventional

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

NCT ID: NCT03983993 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

NIPAVect
Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and panitumumab may work better in treating patients with colorectal cancer.